Overview Intellia Therapeutics, Inc. (we, us, our, Intellia, or the Company) is a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. Our mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, we aim to reset the standard for medicine by durably treating the root causes of di...
Q2 FY2026 — expected 2026-09-15
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-26 | 2025-12-31 | 0001193125-26-076550 | EDGAR | 95K words |
| 2025-02-27 | 2024-12-31 | 0000950170-25-029007 | EDGAR | — |
| 2024-02-22 | 2023-12-31 | 0000950170-24-018736 | EDGAR | — |
| 2023-02-23 | 2022-12-31 | 0000950170-23-004097 | EDGAR | — |
| 2022-02-24 | 2021-12-31 | 0000950170-22-001981 | EDGAR | — |
| 2021-02-26 | 2020-12-31 | 0001564590-21-009011 | EDGAR | — |
| 2020-02-27 | 2019-12-31 | 0001564590-20-007409 | EDGAR | — |
| 2019-02-27 | 2018-12-31 | 0001564590-19-004680 | EDGAR | — |
| 2018-03-14 | 2017-12-31 | 0001564590-18-005544 | EDGAR | — |
| 2017-03-14 | 2016-12-31 | 0001193125-17-082186 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-06 | 2025-09-30 | 0001193125-25-269680 | EDGAR | 62K words |
| 2025-08-07 | 2025-06-30 | 0000950170-25-104987 | EDGAR | — |
| 2025-05-08 | 2025-03-31 | 0000950170-25-066914 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0000950170-24-123276 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0000950170-24-093907 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0000950170-24-057046 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0000950170-23-062011 | EDGAR | — |
| 2023-08-03 | 2023-06-30 | 0000950170-23-037996 | EDGAR | — |
| 2023-05-04 | 2023-03-31 | 0000950170-23-017866 | EDGAR | — |
| 2022-11-03 | 2022-09-30 | 0000950170-22-021835 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0000950170-22-014731 | EDGAR | — |
| 2022-05-05 | 2022-03-31 | 0000950170-22-007805 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-02 | 0001193125-26-084309 | EDGAR | 2K words |
| 2026-02-26 | 0001193125-26-073456 | EDGAR | — |
| 2026-01-27 | 0001193125-26-023387 | EDGAR | — |
| 2026-01-09 | 0001193125-26-008307 | EDGAR | — |
| 2025-11-10 | 0001193125-25-274596 | EDGAR | — |
| 2025-11-06 | 0001193125-25-269479 | EDGAR | — |
| 2025-10-29 | 0001193125-25-256378 | EDGAR | — |
| 2025-10-27 | 0001193125-25-250757 | EDGAR | — |
| 2025-09-25 | 0001193125-25-217484 | EDGAR | — |
| 2025-08-07 | 0000950170-25-104574 | EDGAR | — |
200 total filings indexed. 168 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001652130 |
| Ticker | NTLA |
| Exchange | Nasdaq |
| SIC | 2835: In Vitro & In Vivo Diagnostic Substances |
| Incorporated | DE |
| Website | https://www.intelliatx.com |
| Listed | 2016-05-06 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report